跳至主要内容
临床试验/ISRCTN14796973
ISRCTN14796973已完成未知

Observation on the clinical efficacy and side effects of EGFR-TKI ± chemotherapy in the treatment of EGFR mutation-positive advanced lung adenocarcinoma

Fujian Provincial Hospital0 个研究点目标入组 103 人开始时间: 2022年10月22日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
103

研究概览

简要总结

2022 Results article in https://doi.org/10.1177/1721727X22114544 (added 20/04/2023)

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Initial treatment of lung adenocarcinoma confirmed by pathology or cytology
  • 2. Classic mutation of EGFR gene
  • 3. Minimum life expectancy 3 months
  • 4. Patients with clinical stage III ~ IV were considered as advanced lung cancer after comprehensive evaluation of imaging, medical history and examination at the same time, and were excluded from other malignant tumors

排除标准

  • Does not meet the inclusion criteria

研究者

相似试验